WEIGHT LOSS WITH SUBCUTANEOUS SEMAGLUTIDE VERSUS OTHER GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS IN TYPE 2 DIABETES: A SYSTEMATIC REVIEW